Experimental validation and pan-cancer analysis identified COL10A1 as a novel oncogene and potential therapeutic target in prostate cancer
Figure 4.Kaplan–Meier survival analyses of the prognostic value of COL10A1 expression level for DFS in different cancer types. DFS according to high and low expression of COL10A1 in PAAD, PRAD and SARC from the TCGA database (A–C).